A review of IL-36: an emerging therapeutic target for inflammatory dermatoses
- PMID: 35470744
- DOI: 10.1080/09546634.2022.2067819
A review of IL-36: an emerging therapeutic target for inflammatory dermatoses
Abstract
Background: IL-36 cytokines are members of the IL-1 superfamily. Increasing evidence in the IL-36 pathway demonstrates their potential as a therapeutic target for treating inflammatory skin diseases, such as generalized pustular psoriasis (GPP).
Objective: A narrative review was written to further study preclinical and clinical evidence for the role of IL-36 in psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), acne, autoimmune blistering diseases, and neutrophilic dermatoses.
Results: IL-36 has important downstream effects such as inducing expression of inflammatory cytokines, antimicrobial peptides, and growth factors. Increased expression of IL-36 cytokines has been observed in the lesional skin of patients with psoriasis. Studies of other inflammatory skin diseases have also noted similar findings, albeit to a lesser extent. IL-36 inhibition has been shown to be effective in GPP and is currently being studied for other inflammatory skin diseases.
Conclusions: The IL-36 pathway contributes to pathogenesis of many inflammatory skin diseases and is a promising therapeutic target.
Keywords: IL-36; Psoriasis; atopic dermatitis; hidradenitis suppurativa; imsidolimab; spesolimab.
Similar articles
-
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications.Int J Mol Sci. 2022 Aug 22;23(16):9479. doi: 10.3390/ijms23169479. Int J Mol Sci. 2022. PMID: 36012744 Free PMC article. Review.
-
Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: the gut-skin axis and microbiome-directed therapy.Clin Dermatol. 2023 Sep-Oct;41(5):640-649. doi: 10.1016/j.clindermatol.2023.09.019. Epub 2023 Oct 9. Clin Dermatol. 2023. PMID: 37816413 Review.
-
Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions.Cytokine. 2022 Aug;156:155897. doi: 10.1016/j.cyto.2022.155897. Epub 2022 Jun 6. Cytokine. 2022. PMID: 35679693 Review.
-
Targeting IL-36 in Inflammatory Skin Diseases.BioDrugs. 2023 May;37(3):279-293. doi: 10.1007/s40259-023-00587-5. Epub 2023 Mar 3. BioDrugs. 2023. PMID: 36867370
-
Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation.Int J Mol Sci. 2023 Nov 30;24(23):17014. doi: 10.3390/ijms242317014. Int J Mol Sci. 2023. PMID: 38069342 Free PMC article.
Cited by
-
New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors.Pharmaceutics. 2024 Jul 6;16(7):908. doi: 10.3390/pharmaceutics16070908. Pharmaceutics. 2024. PMID: 39065604 Free PMC article. Review.
-
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.Clin Cosmet Investig Dermatol. 2024 Jan 23;17:159-166. doi: 10.2147/CCID.S449367. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 38283798 Free PMC article.
-
Pathogenesis of Hidradenitis Suppurativa: An Immunological Perspective.Indian J Dermatol. 2023 May-Jun;68(3):296-300. doi: 10.4103/ijd.ijd_594_22. Indian J Dermatol. 2023. PMID: 37529457 Free PMC article. No abstract available.
-
In Silico and In Vitro Analysis of IL36RN Alterations Reveals Critical Residues for the Function of the Interleukin-36 Receptor Complex.J Invest Dermatol. 2023 Dec;143(12):2468-2475.e6. doi: 10.1016/j.jid.2023.06.191. Epub 2023 Jul 4. J Invest Dermatol. 2023. PMID: 37414245 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
